William T Carpenter

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia
    William T Carpenter
    Maryland Psychiatric Research Center, Univeristy of Maryland School of Medicine, USA
    Am J Psychiatry 160:356-62. 2003
  2. ncbi request reprint The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    Robert W Buchanan
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Am J Psychiatry 164:1593-602. 2007
  3. ncbi request reprint Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
  4. pmc Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia
    Gregory P Strauss
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Schizophr Res 135:134-8. 2012
  5. pmc Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome
    Gregory P Strauss
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    J Psychiatr Res 47:783-90. 2013
  6. ncbi request reprint Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
  7. pmc Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
  8. ncbi request reprint Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia
    Adrienne C Lahti
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 31:221-30. 2006
  9. ncbi request reprint Optimistic bias in the perception of personal risk: patterns in schizophrenia
    Kristen J Prentice
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Am J Psychiatry 162:507-12. 2005
  10. ncbi request reprint The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    Celso Arango
    Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
    Am J Psychiatry 160:1421-7. 2003

Detail Information

Publications45

  1. ncbi request reprint The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia
    William T Carpenter
    Maryland Psychiatric Research Center, Univeristy of Maryland School of Medicine, USA
    Am J Psychiatry 160:356-62. 2003
    ..The authors' goal was to consider ethical approaches to placebo-controlled clinical trials in the light of the evolving Declaration of Helsinki, with special attention to applications to research on schizophrenia...
  2. ncbi request reprint The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    Robert W Buchanan
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Am J Psychiatry 164:1593-602. 2007
    ..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments...
  3. ncbi request reprint Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
    ..The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia...
  4. pmc Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia
    Gregory P Strauss
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Schizophr Res 135:134-8. 2012
    ....
  5. pmc Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome
    Gregory P Strauss
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    J Psychiatr Res 47:783-90. 2013
    ..However, it is currently unclear whether negative symptoms themselves are multi-faceted, and whether sub-groups of patients who display unique negative symptom profiles can be identified...
  6. ncbi request reprint Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
    ..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine...
  7. pmc Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
    ..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials...
  8. ncbi request reprint Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia
    Adrienne C Lahti
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 31:221-30. 2006
    ..The involvement of both frontal and parietal regions is implicated in the pathophysiology of negative symptoms...
  9. ncbi request reprint Optimistic bias in the perception of personal risk: patterns in schizophrenia
    Kristen J Prentice
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Am J Psychiatry 162:507-12. 2005
    ..The authors investigated whether schizophrenia patients share the same optimistic biases frequently demonstrated by non-ill adults in their perceptions of personal risk...
  10. ncbi request reprint The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    Celso Arango
    Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
    Am J Psychiatry 160:1421-7. 2003
    ..The study was designed to assess the predictive relationship between brain structure volume and positive and negative symptom response to clozapine and haloperidol...
  11. ncbi request reprint First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
    ....
  12. doi request reprint Lessons to take home from CATIE
    William T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 59:523-5. 2008
    ..Bottom line: the dichotomy between first- and second-generation antipsychotics was not supported by efficacy data (and now, is not supported effectiveness data). Only clozapine has documented superiority in treatment-resistant cases...
  13. ncbi request reprint At issue: A model for academic/industry collaboration
    William T Carpenter
    Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:997-1004. 2004
    ..We discuss the principles involved and the resolutions achieved in the hope that it may provide a useful model for addressing academic/industry scientific collaborations...
  14. ncbi request reprint From clinical trial to prescription
    William T Carpenter
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Arch Gen Psychiatry 59:282-5. 2002
    ..Most hotly debated is the role of money in the creation and dissemination of knowledge...
  15. pmc Evidence-based therapeutics--introducing the Cochrane corner
    William T Carpenter
    Schizophr Bull 33:633-4. 2007
  16. doi request reprint Participants with schizophrenia retain the information necessary for informed consent during clinical trials
    Bernard A Fischer
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    J Clin Psychiatry 74:622-7. 2013
    ..Stability was defined as being on an antipsychotic with no change in medication or dose over the previous 4 weeks...
  17. ncbi request reprint Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia
    L Elliot Hong
    Department of Psychiatry, Maryland Psychiatric Research Center, School of Medicine, University of Maryland, Baltimore, 21228, USA
    Am J Med Genet B Neuropsychiatr Genet 136:8-11. 2005
    ..2%, P =0.050) forms of schizophrenia compared to controls (allele frequency 25.0%). We conclude that the DRP-2 *2236 C allele may mark another polymorphism in DRP-2, or in a nearby gene, that may influence susceptibility to schizophrenia...
  18. doi request reprint Revisiting the diagnosis of schizophrenia: where have we been and where are we going?
    William R Keller
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
    CNS Neurosci Ther 17:83-8. 2011
    ....
  19. pmc White matter alterations in deficit schizophrenia
    Laura M Rowland
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 34:1514-22. 2009
    ..These findings provide further support for altered frontal-parietal network in deficit schizophrenia...
  20. pmc The evolution of drug development in schizophrenia: past issues and future opportunities
    William T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 33:2061-79. 2008
    ..Success in drug discovery for cognition and negative symptom pathologies may bring forth issues in ethics as the potential for enhancing normal function is explored...
  21. ncbi request reprint Clinical constructs and therapeutic discovery
    William T Carpenter
    University of Maryland Baltimore, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 72:69-73. 2004
    ..Antipsychotic drugs fail to address these pathologies. These unmet treatment needs are clinical targets for drug discovery involving novel therapeutic pathways...
  22. ncbi request reprint Commentary on the Soteria project: misguided therapeutics
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore 21228, USA
    Schizophr Bull 28:577-81; discussion 583-8. 2002
  23. pmc Will the Kraepelinian dichotomy survive DSM-V?
    Bernard A Fischer
    Department of Psychiatry, Maryland Psychiatric Research Center, VA Capitol Health Care Network VISN 5 MIRECC and University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 34:2081-7. 2009
    ..An alternative paradigm based on domains of pathology is more powerful for studies of etiology, pathophysiology, and therapeutic discovery...
  24. ncbi request reprint Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD21228, USA
    J Nerv Ment Dis 190:593-6. 2002
  25. ncbi request reprint Challenge to atypical antipsychotic drug effect on cognition
    William T Carpenter
    Am J Psychiatry 164:1910-1; author reply 1911-2. 2007
  26. ncbi request reprint Clarifying standards for using placebos
    Robert J Levine
    Science 300:1659-61. 2003
  27. ncbi request reprint First- and second-generation antipsychotics: learning from CUtLASS and CATIE
    Rajiv Tandon
    Arch Gen Psychiatry 64:977-8; author reply 979-80. 2007
  28. pmc Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge
    Thomas H McGlashan
    Department of Psychiatry, Yale University, USA
    Schizophr Bull 33:1086-92. 2007
    ..The results have radically changed the paradigm for discovery with emphasis on impaired cognition and negative symptom psychopathology...
  29. pmc Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date
    Alex S Cohen
    Department of Psychology, University of Maryland, College Park, USA
    Schizophr Bull 33:1201-12. 2007
    ..The question of whether deficit patients exhibit a unique cognitive impairment profile will require a more sophisticated and rigorous examination of the neuropsychology of the deficit syndrome...
  30. ncbi request reprint Another view of therapy for cognition in schizophrenia
    William T Carpenter
    Biol Psychiatry 51:969-71. 2002
  31. ncbi request reprint Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  32. ncbi request reprint The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms
    Celso Arango
    Servicio de Psiquiatria, Hospital General Gregorio Maranon, C Ibiza 43, 280079 Madrid, Spain
    Eur Psychiatry 19:21-6. 2004
    ..The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of this distinctive aspect of schizophrenia...
  33. ncbi request reprint The costs of drugs for schizophrenia
    Robert Freedman
    Am J Psychiatry 163:2029-31. 2006
  34. pmc The NIMH-MATRICS consensus statement on negative symptoms
    Brian Kirkpatrick
    Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    Schizophr Bull 32:214-9. 2006
  35. pmc Treatment of schizophrenia negative symptoms: future prospects
    Stephen M Erhart
    UCLA Department of Psychiatry and Biobehavioral Sciences, USA
    Schizophr Bull 32:234-7. 2006
    ..We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments...
  36. ncbi request reprint Targeting schizophrenia research to patient outcomes
    William T Carpenter
    Am J Psychiatry 163:353-5. 2006
  37. ncbi request reprint The schizophrenia paradigm: a hundred-year challenge
    William T Carpenter
    J Nerv Ment Dis 194:639-43. 2006
  38. ncbi request reprint The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study
    Robert R Conley
    J Clin Psychopharmacol 23:668-71. 2003
  39. ncbi request reprint Summer birth and deficit schizophrenia: a pooled analysis from 6 countries
    Erick Messias
    Department of Psychiatry, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Arch Gen Psychiatry 61:985-9. 2004
    ..In some reports, summer birth has been associated with deficit schizophrenia. Deficit schizophrenia and nondeficit schizophrenia also differ in several other ways...
  40. ncbi request reprint Was Joan of Arc criminally, responsible for her acts alleged of heresy?
    Karen Sullivan
    Bard College, Annandale on Hudson, New York, USA
    Pharos Alpha Omega Alpha Honor Med Soc 67:4-11. 2004
  41. ncbi request reprint Neuroplasticity and schizophrenia
    Douglas O Frost
    Department of Pharmacology and Experimental Therapeutics, Baltimore, Maryland, USA
    Biol Psychiatry 56:540-3. 2004
    ..Although the focus of this workshop was schizophrenia, the phenomena considered are pertinent to other disorders, such as depression and drug abuse...
  42. ncbi request reprint Maintaining informed consent validity during lengthy research protocols
    Kristen J Prentice
    University of Maryland School of Medicine, USA
    IRB 29:1-6. 2007
  43. ncbi request reprint Association between polymorphism of the SNAP29 gene promoter region and schizophrenia
    Ikwunga Wonodi
    Schizophr Res 78:339-41. 2005
  44. ncbi request reprint Schizophrenia: disease, syndrome, or dimensions?
    William T Carpenter
    Fam Process 46:199-206. 2007
    ..This view has been challenged by a series of studies during the past three decades. These investigations are summarized in this report. Implications for clinical work with families are considered...
  45. pmc Traditional ethics and new sensitivities
    William T Carpenter
    Schizophr Bull 32:1-2. 2006